BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23434829)

  • 1. Upregulation of drug transporter expression by osteopontin in prostate cancer cells.
    Hsieh IS; Huang WH; Liou HC; Chuang WJ; Yang RS; Fu WM
    Mol Pharmacol; 2013 May; 83(5):968-77. PubMed ID: 23434829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
    Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
    Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells.
    Chen YJ; Wei YY; Chen HT; Fong YC; Hsu CJ; Tsai CH; Hsu HC; Liu SH; Tang CH
    J Cell Physiol; 2009 Oct; 221(1):98-108. PubMed ID: 19475568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.
    Cui R; Takahashi F; Ohashi R; Gu T; Yoshioka M; Nishio K; Ohe Y; Tominaga S; Takagi Y; Sasaki S; Fukuchi Y; Takahashi K
    Lung Cancer; 2007 Sep; 57(3):302-10. PubMed ID: 17482311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
    Mi Z; Guo H; Wai PY; Gao C; Kuo PC
    Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin-integrin α(v)β(3) axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma.
    Nakamura T; Shinriki S; Jono H; Ueda M; Nagata M; Guo J; Hayashi M; Yoshida R; Ota T; Ota K; Kawahara K; Nakagawa Y; Yamashita S; Nakayama H; Hiraki A; Shinohara M; Ando Y
    FEBS Lett; 2015 Jan; 589(2):231-9. PubMed ID: 25497015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression.
    Zhang Y; Forootan SS; Kamalian L; Bao ZZ; Malki MI; Foster CS; Ke Y
    Int J Oncol; 2011 Apr; 38(4):1083-91. PubMed ID: 21290088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of osteopontin downregulation on the growth of prostate cancer PC-3 cells.
    Zheng J; Hou ZB; Jiao NL
    Mol Med Rep; 2011; 4(6):1225-31. PubMed ID: 21842122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
    Liu H; Chen A; Guo F; Yuan L
    Cancer Lett; 2010 Sep; 295(1):27-37. PubMed ID: 20207476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
    Yang L; Wei L; Zhao W; Wang X; Zheng G; Zheng M; Song X; Zuo W
    Mol Med Rep; 2012 Feb; 5(2):373-6. PubMed ID: 22143930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma.
    Weismann D; Briese J; Niemann J; Grüneberger M; Adam P; Hahner S; Johanssen S; Liu W; Ezzat S; Saeger W; Bamberger AM; Fassnacht M; Schulte HM; Asa SL; Allolio B; Bamberger CM
    J Pathol; 2009 Jun; 218(2):232-40. PubMed ID: 19326399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin.
    Liu J; Ren Y; Kang L; Zhang L
    Int J Mol Med; 2014 May; 33(5):1341-7. PubMed ID: 24590381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9.
    Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
    Am J Pathol; 2014 Mar; 184(3):842-58. PubMed ID: 24412090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells.
    Lee JL; Wang MJ; Sudhir PR; Chen GD; Chi CW; Chen JY
    Cancer Res; 2007 Mar; 67(5):2089-97. PubMed ID: 17332338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3.
    Graessmann M; Berg B; Fuchs B; Klein A; Graessmann A
    Oncogene; 2007 May; 26(20):2840-50. PubMed ID: 17160024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
    Desai B; Rogers MJ; Chellaiah MA
    Mol Cancer; 2007 Mar; 6():18. PubMed ID: 17343740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
    Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
    Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin O-glycosylation contributes to its phosphorylation and cell-adhesion properties.
    Kariya Y; Kanno M; Matsumoto-Morita K; Konno M; Yamaguchi Y; Hashimoto Y
    Biochem J; 2014 Oct; 463(1):93-102. PubMed ID: 25000122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
    Tajima K; Ohashi R; Sekido Y; Hida T; Nara T; Hashimoto M; Iwakami S; Minakata K; Yae T; Takahashi F; Saya H; Takahashi K
    Oncogene; 2010 Apr; 29(13):1941-51. PubMed ID: 20101228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.
    Ohashi R; Tajima K; Takahashi F; Cui R; Gu T; Shimizu K; Nishio K; Fukuoka K; Nakano T; Takahashi K
    Anticancer Res; 2009 Jun; 29(6):2205-14. PubMed ID: 19528482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.